Jun. 23 at 6:13 PM
$LLY to acquire
$VERV for up to
$1.3B
Depending on future milestones, Lilly will pay
$10.50/share in cash, or roughly
$1B, plus a contingent value right of up to
$3.00/share.
The purchase is anticipated to be completed in 3Q25
Verve's flagship program VERVE-102 targets PCSK9 - the medication, which is currently in Phase 1b & has been granted FDA Fast Track designation, has the potential to transform care for patients suffering from heterozygous familial hypercholesterolemia & early coronary artery disease.
VERVE-101, encountered safety concerns and Verve decided to scrap it in favor of a successor, VERVE-102, that used a different lipid nanoparticle for delivery of the treatment.
According to Lilly, Verve’s platform strengthens its cardiometabolic pipeline. Verve’s medicine “could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment"
